Jiangsu Kanion Pharmaceutical Co Ltd (SHG:600557) — Market Cap & Net Worth
Market Cap & Net Worth: Jiangsu Kanion Pharmaceutical Co Ltd (600557)
Jiangsu Kanion Pharmaceutical Co Ltd (SHG:600557) has a market capitalization of $1.11 Billion (CN¥7.60 Billion) as of May 7, 2026. Listed on the SHG stock exchange, this China-based company holds position #8686 globally and #2284 in its home market, demonstrating a -7.12% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Jiangsu Kanion Pharmaceutical Co Ltd's stock price CN¥13.43 by its total outstanding shares 566158806 (566.16 Million). Analyse Jiangsu Kanion Pharmaceutical Co Ltd operating cash flow efficiency to see how efficiently the company converts income to cash.
Jiangsu Kanion Pharmaceutical Co Ltd Market Cap History: 2015 to 2026
Jiangsu Kanion Pharmaceutical Co Ltd's market capitalization history from 2015 to 2026. Data shows change from $1.68 Billion to $1.11 Billion (-3.15% CAGR).
Jiangsu Kanion Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Jiangsu Kanion Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.29x
Jiangsu Kanion Pharmaceutical Co Ltd's market cap is 0.29 times its annual revenue
Latest Price to Earnings (P/E) Ratio
2.88x
Jiangsu Kanion Pharmaceutical Co Ltd's market cap is 2.88 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.68 Billion | $2.82 Billion | $362.34 Million | 0.60x | 4.65x |
| 2016 | $1.37 Billion | $3.00 Billion | $373.74 Million | 0.46x | 3.68x |
| 2017 | $1.10 Billion | $3.27 Billion | $373.78 Million | 0.34x | 2.94x |
| 2018 | $841.96 Million | $3.82 Billion | $414.05 Million | 0.22x | 2.03x |
| 2019 | $1.21 Billion | $4.57 Billion | $506.99 Million | 0.27x | 2.40x |
| 2020 | $842.55 Million | $3.03 Billion | $262.92 Million | 0.28x | 3.20x |
| 2021 | $1.01 Billion | $3.65 Billion | $320.54 Million | 0.28x | 3.16x |
| 2022 | $1.55 Billion | $4.35 Billion | $434.47 Million | 0.36x | 3.58x |
| 2023 | $1.70 Billion | $4.86 Billion | $464.16 Million | 0.35x | 3.66x |
| 2024 | $1.13 Billion | $3.90 Billion | $391.86 Million | 0.29x | 2.88x |
Competitor Companies of 600557 by Market Capitalization
Companies near Jiangsu Kanion Pharmaceutical Co Ltd in the global market cap rankings as of May 7, 2026.
Key companies related to Jiangsu Kanion Pharmaceutical Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #501 globally with a market cap of $52.60 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #530 globally with a market cap of $50.06 Billion USD ( CN¥342.11 Billion CNY).
- Zoetis Inc (NYSE:ZTS): Ranked #541 globally with a market cap of $49.01 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #574 globally with a market cap of $45.88 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #501 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #530 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.06 Billion | CN¥53.63 |
| #541 | Zoetis Inc | NYSE:ZTS | $49.01 Billion | $111.22 |
| #574 | GALDERMA GROUP AG | NYSE:GALDY | $45.88 Billion | $43.83 |
Jiangsu Kanion Pharmaceutical Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Jiangsu Kanion Pharmaceutical Co Ltd's market cap moved from $1.68 Billion to $ 1.11 Billion, with a yearly change of -3.15%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.11 Billion | -4.82% |
| 2025 | CN¥1.17 Billion | +3.60% |
| 2024 | CN¥1.13 Billion | -33.63% |
| 2023 | CN¥1.70 Billion | +9.44% |
| 2022 | CN¥1.55 Billion | +53.19% |
| 2021 | CN¥1.01 Billion | +20.35% |
| 2020 | CN¥842.55 Million | -30.62% |
| 2019 | CN¥1.21 Billion | +44.23% |
| 2018 | CN¥841.96 Million | -23.37% |
| 2017 | CN¥1.10 Billion | -20.08% |
| 2016 | CN¥1.37 Billion | -18.41% |
| 2015 | CN¥1.68 Billion | -- |
End of Day Market Cap According to Different Sources
On May 7th, 2026 the market cap of Jiangsu Kanion Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.11 Billion USD |
| MoneyControl | $1.11 Billion USD |
| MarketWatch | $1.11 Billion USD |
| marketcap.company | $1.11 Billion USD |
| Reuters | $1.11 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Jiangsu Kanion Pharmaceutical Co Ltd
Jiangsu Kanion Pharmaceutical Co.,Ltd. researches and develops, produces, and sells Chinese medicines. It also offers medicines in the fields of anti-infections, orthopedics, gynecology, cardio and cerebrovascular, tonic-class, and others. In addition, the company provides herb extracts and formula granules, as well as OEM/ODM services. Jiangsu Kanion Pharmaceutical Co.,Ltd. was founded in 1975 a… Read more